Entering text into the input field will update the search result below

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2020 Results - Earnings Call Transcript

Mar. 02, 2021 4:02 PM ETEagle Pharmaceuticals, Inc. (EGRX)
SA Transcripts profile picture
SA Transcripts

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET

Company Participants

Lisa Wilson - IR

Scott Tarriff - CEO

Brian Cahill - CFO

David Pernock - President and COO

Judith Ng-Cashin - Chief Medical Officer

Conference Call Participants

Randall Stanicky - RBC Capital Markets

Tim Lugo - William Blair

Brandon Folkes - Cantor Fitzgerald


Good morning, everyone. My name is Leo. And I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review Call.

All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer period. [Operator Instructions] As a reminder, this conference call is being recorded today, March 2, 2021.

It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, operator. Welcome to Eagle Pharmaceuticals’ fourth quarter 2020 earnings and pipeline review call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle’s Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill, President and Chief Operating Office; David Pernock and Chief Financial Officer, Dr. Judith Ng-Cashin.

This morning, the company issued a press release detailing financial results for the three months ended December 31, 2020. This press release and a webcast of this call can be accessed through the Investors' section of the Eagle website at eagleus.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events in the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.